Lucid Diagnostics Inc. (NASDAQ:LUCD) Financings

Lucid Diagnostics Inc.

Financings

RaiseDate
Private placement of series C Convertible Preferred Stock
Closed: US$15M raised · US$1,000 a share
Buyers: Holders of a majority of the Company's 12.0% senior secured convertible notes due 2029
Use of proceeds: To accelerate near-term commercial operations and for working capital and general corporate purposes
Oct 22, 2026
Registered direct offering of common shares
Closed: US$18M raised · US$1 a share · Canaccord Genuity LLC +1
Dealers: Canaccord Genuity LLC (co-lead), BTIG, LLC (co-lead)
Buyers: fundamental institutional investor ($15 million investment)
Use of proceeds: Working capital and general corporate purposes
Apr 24, 2026
Public offering of common stock
Closed: US$26.9M raised · US$1 a share · Canaccord Genuity LLC +2
Dealers: Canaccord Genuity LLC (co-lead), BTIG, LLC (co-lead), Maxim Group LLC
Use of proceeds: Working capital and general corporate purposes
Sep 11, 2025
Public offering of common stock
Closed: US$16.1M raised
May 14, 2025
Registered direct offering of shares of common stock
Closed: US$15.3M raised · US$1.1 a share · Canaccord Genuity
Dealers: Canaccord Genuity (lead)
Use of proceeds: Working capital and other general corporate purposes
Mar 5, 2025
Five-year convertible notes
Closed: US$21.95M raised
Use of proceeds: $3.61 million used to retire existing convertible debt; remainder adds cash to extend runway past reimbursement milestones
Dec 3, 2024

Read by 6ix AI from the company's releases